We are live on ! Find out more
GLUE icon

Monte Rosa Therapeutics
GLUE

104 hedge funds and large institutions have $423M invested in Monte Rosa Therapeutics in 2024 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 36 increasing their positions, 17 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,265% more call options, than puts

Call options by funds: $2.21M | Put options by funds: $162K

209% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 11

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

112% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 17

61% more capital invested

Capital invested by funds: $264M → $423M (+$160M)

28% more funds holding

Funds holding: 81 → 104 (+23)

18.19% more ownership

Funds ownership: 81.07% → 99.26% (+18%)

Holders
104
Holders Change
+23
Holders Change %
+28.4%
% of All Funds
1.37%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
34
Increased
36
Reduced
17
Closed
11
Calls
$2.21M
Puts
$162K
Net Calls
+$2.05M
Net Calls Change
+$1.32M

Top Buyers

Rank Fund Capital Flow
1
VVM
Versant Venture Management
California
+$42.4M
2
BI
BVF Inc
California
+$20.7M
3
Morgan Stanley
Morgan Stanley
New York
+$16M
4
BlackRock
BlackRock
New York
+$7.04M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$4.67M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$10.8M
2
SCM
Suvretta Capital Management
New York
-$8.22M
3
VPC
Vestal Point Capital
New York
-$3.79M
4
Citadel Advisors
Citadel Advisors
Florida
-$2.86M
5
ECM
ExodusPoint Capital Management
New York
-$2.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
CIAM
101
Caitong International Asset Management
Hong Kong
$257 +$278 +37 New
PNC Financial Services Group
102
PNC Financial Services Group
Pennsylvania
$194 – – –
US Bancorp
103
US Bancorp
Minnesota
$180 +$195 +26 New
IA
104
IFP Advisors
Florida
$42 – – –
EWA
105
EverSource Wealth Advisors
Alabama
$28 +$30 +4 New
ECM
106
ExodusPoint Capital Management
New York
– -$2.09M -393,586 Closed
SFM
107
Sphera Funds Management
Israel
– -$626K -118,103 Closed
Acadian Asset Management
108
Acadian Asset Management
Massachusetts
– -$586K -110,835 Closed
HF
109
HRT Financial
New York
– -$206K -38,911 Closed
EC
110
EntryPoint Capital
New York
– -$176K -33,219 Closed
BCM
111
Bridgeway Capital Management
Texas
– -$133K -25,000 Closed
UBS AM
112
UBS AM
Illinois
– -$128K -24,100 Closed
CIC
113
Cornercap Investment Counsel
Georgia
– -$102K -19,236 Closed
MAM
114
Meeder Asset Management
Ohio
– -$53.3K -10,050 Closed
SO
115
STRS Ohio
Ohio
– -$16.4K -3,100 Closed
CPA
116
Capital Performance Advisors
California
– -$154 -29 Closed
1 2 3 4
5

GLUE Hedge Fund Activity: Q4 2024 in Review

104 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q4 2024, worth a combined $423M — up 61% from $264M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new GLUE positions and 11 closed out — a net gain of 23 holders — while 36 added to existing stakes and 17 trimmed.

The largest buyer was Versant Venture Management, opening a new position worth an estimated $42.4M. The largest seller was Avoro Capital Advisors, cutting an estimated $10.8M.

  • 104 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q4 2024, up from 81 in Q3 2024.
  • Funds reported $423M of Monte Rosa Therapeutics stock for Q4 2024, up 61% quarter-over-quarter.
  • 34 funds opened new Monte Rosa Therapeutics positions in Q4 2024 and 11 closed out, a net change of +23 holders.
  • The largest Monte Rosa Therapeutics buyer in Q4 2024 was Versant Venture Management, an estimated $42.4M added.
  • The largest Monte Rosa Therapeutics seller in Q4 2024 was Avoro Capital Advisors, an estimated $10.8M sold.

Based on aggregated 13F filings for Q4 2024.